Zydus Lifesciences rises on getting USFDA`s final nod for Eltrombopag Tablets
Zydus Lifesciences is currently trading at Rs. 886.90, up by 2.90 points or 0.33% from its previous closing of Rs. 884.00 on the BSE.
The scrip opened at Rs. 888.00 and has touched a high and low of Rs. 890.00 and Rs. 878.60 respectively. So far 15926 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1059.00 on 19-Sep-2025 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 913.00 and Rs. 878.60 respectively. The current market cap of the company is Rs. 88764.93 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 18.15% and 6.85% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg (USRLD: Promacta Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg).
Eltrombopag tablets are indicated for the treatment of thrombocytopenia (low platelet count) in specific blood disorders. Eltrombopag works by stimulating bone marrow cells to produce more platelets, thereby reducing the risk of bleeding. Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad.
Eltrombopag tablets had annual sales of $1262.5 million in the United States (IQVIA MAT Nov-2025). The group now has 429 approvals and has so far filed 505 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
